Serina Therapeutics, Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
Steve Ledger (CEO) and Gregory S. Curhan (CFO) issued standard Sarbanes-Oxley Sections 302 and 906 certifications for the Q2 2026 (ended June 30, 2026) 10-Q filing dated August 13, 2026. Both officers certified that financial statements fairly present the company's condition and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or fraud were disclosed.
Why this rating
Routine SOX certification exhibits. No substantive business developments, financial data, or material changes disclosed here.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.